Lexicon Pharma (LXRX) Posts Q3 Loss of $0.14
More News related to LXRX
- Lexicon Pharma (LXRX) to Present LX1031 Phase 2 Results at GASTRO 2009
- Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
- Morning Movers 11/13: CNIC, TSTC, NLST, AGO, SLI Higher; LIME, GMET, BIOF, DISK, MRGE, SSY Lower
- After-Hours Movers 11/12: TSTC, LXRX, MDSO Higher; DISK, MRNA, LIME, BBI, ESE, JWN Lower
- Lexicon Pharma (LXRX) Announces LX1031 Shows Positive Results on Irritable Bowel Syndrome
Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) reports Q3 loss of $0.14, 3 cents better than the analyst estimate of ($0.17). Revenue for the quarter was $2.13 million, which compares to the estimate of $1.63 million.
Related Categories
EarningsGuidance
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
